Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd

Bullboard Posts

Comment by Covid19on Mar 22, 2020 3:32am

659 Views

Post# 30834620

RE:TOP HOT 6 - VXL #1

wanttoretireearly wrote:

Illustrating the interest in coronavirus-related healthcare today, the most-viewed company on the healthcare Bullboards was also the most-viewed across all other sectors on Stockhouse. The interest in Vaxil Bio Ltd. (TSX-V:VXL, Forum) began back in Feb. 13, and shares of the Israel-based immune-oncology company started to climb rapidly in price and volume from $0.03 on Feb. 13 to $0.14 on Feb. 18. More recently, VXL climbed from $0.115 on Mar. 9 to $0.31 on Mar. 12 before falling back down to $0.17.

The news that propelled Vaxil Bio was what everyone has been looking for, a potential COVID-19 vaccine. On Feb. 13, the company announced it had identified a vaccine candidate, and on Feb. 18 further clarified the patent protected technology behind the potential vaccine. The timing couldn’t have been better for VXL, as the company had been in the process of a bridge financing. On Mar. 10, it took the biggest step, applying for a US patent for a coronavirus vaccine.
But Vaxil is just one of now 41 (!) companies that the World Health Organization identifies as working towards a COVID-19 vaccine, so will it “win” out? The VXL Bullboard noted the positives in the company’s favor, including CEO David Goren and his experience as a veteran executive of pharma giant Pfizer Inc. (NYSE:PFE), and the fact that pharma majors looking to enter the race make companies like Vaxil good buyout targets. At the end of the day, as Stockhouse Member LongTbuffet pointed out, it doesn’t matter what comes down the pipeline at this point, as long as it’s a step forward.

“We are one good news away to a possible 5X gains here. This pandemic has created fear and urgency. Testing will be rushed and the FDA will try its best to get a vaccine out.”

https://stockhouse.com/opinion/buzz-on-the-bullboards/2020/03/19/buzz-on-bullboards-hot-coronavirus-healthcare-stocks